These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31959346)

  • 1. Vemurafenib in non-small-cell lung cancer patients with BRAF
    Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY
    Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF
    Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
    ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
    Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
    N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With
    Subbiah V; Gervais R; Riely G; Hollebecque A; Blay JY; Felip E; Schuler M; Gonçalves A; Italiano A; Keedy V; Chau I; Puzanov I; Raje NS; Meric-Bernstam F; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encorafenib plus binimetinib in patients with
    Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
    Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
    Sosman JA; Kim KB; Schuchter L; Gonzalez R; Pavlick AC; Weber JS; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Hersey P; Kefford R; Lawrence D; Puzanov I; Lewis KD; Amaravadi RK; Chmielowski B; Lawrence HJ; Shyr Y; Ye F; Li J; Nolop KB; Lee RJ; Joe AK; Ribas A
    N Engl J Med; 2012 Feb; 366(8):707-14. PubMed ID: 22356324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, multicentre safety study of vemurafenib in patients with BRAF
    Larkin J; Brown MP; Arance AM; Hauschild A; Queirolo P; Vecchio MD; Ascierto PA; Krajsová I; Schachter J; Neyns B; Garbe C; Sileni VC; Mandalà M; Gogas H; Espinosa E; Hospers G; Lorigan P; Nyakas M; Guminski A; Liszkay G; Rutkowski P; Miller W; Donica M; Makrutzki M; Blank C
    Eur J Cancer; 2019 Jan; 107():175-185. PubMed ID: 30580112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
    Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
    Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
    Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
    Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
    Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib in Chinese patients with BRAF
    Si L; Zhang X; Xu Z; Jiang Q; Bu L; Wang X; Mao L; Zhang W; Richie N; Guo J
    BMC Cancer; 2018 May; 18(1):520. PubMed ID: 29724167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With
    Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA
    J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
    Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
    Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
    Clark JI; Singh J; Ernstoff MS; Lao CD; Flaherty LE; Logan TF; Curti B; Agarwala SS; Taback B; Cranmer L; Lutzky J; Luna TL; Aung S; Lawson DH
    J Immunother Cancer; 2018 Jul; 6(1):76. PubMed ID: 30053905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.